Please Wait.....
Report
European Life Science Tools and Reagents Market
Market Research Report I 2024-09-11 I 128 Pages I BCC Research
Description
Report Scope
This report provides a comprehensive analysis of the European market for life science tools and reagents, including the leading companies, their revenues, product portfolios and recent activities. It looks at the competitive landscape, trends and market dynamics, such as drivers, restraints and opportunities. It also analyzes the current and future markets. The reagents studied are antibodies, enzyme-linked immunosorbent assay (ELISA) kits, protein reagents and probes. The life science tools included are hybridization systems, PCR, Western blotting instruments and ELISA instruments. The countries whose markets are analyzed are Germany, France, the U.K., Italy, Spain, Switzerland and the Rest of Europe. Markets are also analyzed by application.
Report Includes
- 33 data tables and 54 additional tables
- An analysis of the European market for life science tools and reagents, including COVID-19 diagnostics products
- Analyses of the market trends, with historic market revenue data (sales figures) for 2021-2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the market size and revenue forecasts for the market for life science tools and reagents, with market share analysis by product, application, and country
- Discussions of the market dynamics, opportunities and challenges, as well as emerging technologies
- Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices of leading companies, their ESG scores, and consumer attitudes
- Competitive intelligence, including companies' market shares, recent M&A activity and venture funding
- Profiles of the leading companies, including Thermo Fisher Scientific Inc., Danaher Corp., Merck KGaA, Qiagen and Roche
Executive Summary
Summary:
One of Europe's most significant strategic assets is the life science industry, which produces cuttingedge drugs and vaccines essential to the long-term health and security of European residents.
Innovation in the field of life science has transformed the trajectory of a number of diseases. According to the EFPIA article on Competitiveness Strategy for European Life Science, HIV, which was once considered a deadly disease, has now been changed to a manageable disease, significant advances in cancer care have transformed survival rates, 95% of patients can now be cured of hepatitis C, and new tools have been developed to manage cardiovascular diseases and obesity.
During the 1980s Europe was considered the global leader in pharmaceutical discovery, development and manufacturing. However, that position has gradually been ceded to the U.S., which is currently dominating the global healthcare industry. Of the top 50 global pharmaceutical companies, only 10 are headquartered in Europe. As the highest revenue-generating companies will invest more in R&D, U.S. companies are expected to hold a competitive edge in the near future.
A recent report published in 2023, as an initiative of Biomed Alliance in Europe, EuropaBio, and Johnson & Johnson, highlights that by 2021, the public investments in healthcare research in the U.S. reached $43.6 billion (EUR40 billion), compared to $9.4 billion (EUR8.4 billion) annually in the Europe. The number of clinical trials conducted in European countries is also lower than in the U.S. In addition, as emerging markets such as China and Korea continue to expand, research activity is moving from Europe to these regions. Therefore, it is imperative for the European government to take certain measures to regain its position in the healthcare industry. Such measures include slowly increasing spending on research and ensuring research and development activities are not moving to other countries in the future.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Product Development in Life Science
Chapter 3 Market Dynamics
Global Market Dynamics
Market Drivers
Increasing Investments in R&D
Increasing Prevalence of Chronic Diseases
Increasing Demand for Various Diagnostics Pathways and In Vitro Diagnostics
Growth in Genomic and Biomarker Research
Increasing Demand for Personalized Medicine
Technological Advances
Market Restraints
End of COVID-19 Pandemic
High Cost of Instruments
Lack of Skilled Personnels
Market Challenges
Regulatory Hurdles
Market Opportunities
Positive Impact from Some Revisions in Pharmaceutical Legislation
New Technologies
Chapter 4 Emerging Technologies and Developments
Overview
Next-Generation Therapeutics
Next-Generation Diagnostics
Digitalization
AI and Machine Learning
Internet of Things (IoT)
Robots in Life Science Labs
Chapter 5 Market Segmentation Analysis
Overview
Segmentation Breakdown
European Market for Life Science Tools and Diagnostics, by Product Type
COVID-19 Diagnostic Tests Market
Market for Life Science Tools and Reagents
European Market for Life Science Tools and Diagnostics, by Application
Genomics
Proteomics
Cell Biology, Antibodies and Recombinant Proteins
Stem Cells Research
Imaging Tools and Techniques
Animal Models
Epigenetics
Metabolomics
Other Applications
Europe
United Kingdom
Germany
France
Switzerland
Spain
Italy
Rest of Europe
Chapter 6 Competitive Intelligence
PCR Technologies and Reagents
Antibodies
ELISA Instruments
ELISA Kits and Assays
Life Science Kits and Assays
COVID-19 Diagnostics
Strategic Initiatives
Recent Product Introductions in the Market
Chapter 7 Sustainability in Life Science Tools and Reagents in the European Market: An ESG Perspective
Introduction to ESG
ESG Practices in the Industry
Status of ESG in the Industry
Concluding Remarks from BCC
Chapter 8 Appendix
Methodology
Acronyms
Sources
Company Profiles
AGILENT TECHNOLOGIES INC.
ALTONA DIAGNOSTICS GMBH
ANALYTIK JENA GMBH+CO. KG
BD
BIO-RAD LABORATORIES INC.
DANAHER CORP.
F. HOFFMANN-LA ROCHE LTD.
MERCK KGAA
PROMEGA CORP.
QIAGEN
REVVITY INC.
THERMO FISHER SCIENTIFIC INC.
List of Tables
Summary Table : European Market for Life Science Tools and COVID-19 Diagnostics, by Product Type, Through 2029
Table 1 : Differences Between Basic and Applied Research
Table 2 : Pharmaceutical Industry R&D Expenditures in Europe, by Select Countries, 2022
Table 3 : Cancer Cases in Europe for Both Sexes, 2022
Table 4 : European Market for Life Science Tools and COVID-19 Diagnostics, by Product Type, Through 2029
Table 5 : European Market for COVID-19 Diagnostics Tests, by Type, Through 2029
Table 6 : European Market for COVID-19 Molecular Tests, by Country, Through 2029
Table 7 : European Market for COVID-19 Antigen Tests, by Country, Through 2029
Table 8 : European Market for COVID-19 Serological Tests, by Country, Through 2029
Table 9 : European Market for Life Science Tools and Reagents, by Type, Through 2029
Table 10 : European Market for Life Science Instruments, by Country, Through 2029
Table 11 : European Market for Life Science Reagents and Kits, by Country, Through 2029
Table 12 : European Market for Life Science Tools and Reagents, by Application, Through 2029
Table 13 : European Market for Genomics, by Country, Through 2029
Table 14 : Drug Targets Identified by Proteomics
Table 15 : European Market for Proteomics, by Country, Through 2029
Table 16 : European Market for Cell Biology, Antibodies and Recombinant Proteins, by Country, Through 2029
Table 17 : European Market for Stem Cell Research, by Country, Through 2029
Table 18 : European Market for Imaging Tools and Techniques, by Country, Through 2029
Table 19 : European Market for Animal Models, by Country, Through 2029
Table 20 : European Market for Epigenetics, by Country, Through 2029
Table 21 : European Market for Metabolomics, by Country, Through 2029
Table 22 : European Market for Other Applications of Life Science Tools and Reagents, by Country, Through 2029
Table 23 : European Based Companies' R&D Expenditures and Comparison of Their Net Sales, 2023
Table 24 : European Market for Life Science Tools and Reagents, by Country, Through 2029
Table 25 : European Market for Life Science COVID-19 Diagnostics Tests, by Country, Through 2029
Table 26 : Ranking of Life Science Tool and Reagent Companies in Europe, 2023
Table 27 : Leading Providers of PCR Technologies, by Revenue, 2023
Table 28 : Leading Suppliers of Research Antibodies, 2023
Table 29 : Leading Providers of ELISA Instruments/Microplate Readers, 2023
Table 30 : Leading Providers of ELISA Kits and Assays, 2023
Table 31 : Ranking of Leading Suppliers of Kits and Assays, 2023
Table 32 : Ranking of Leading Providers of COVID-19 Diagnostics Tools, 2023
Table 33 : Collaborations in the Life Science Tools and Reagents Market, 2020-2024
Table 34 : Mergers and Acquisitions in the Life Science Tools and Reagents Market, 2021-2024
Table 35 : Recent New Life Science Tools and Reagents, 2021-2024
Table 36 : Key Focus Areas in ESG Metrics
Table 37 : Environmental Initiatives by Various Life Science Tools, Reagents and Diagnostics Companies and Some of their Initiatives in Europe
Table 38 : Key Social and Governance Issues in the Life Science Tools, Reagents and Diagnostics Industry
Table 39 : ESG Rankings for Companies in the Life Science Tools and Reagents Market, 2023
Table 40 : Glossary of Terms Used in This Report
Table 41 : Information Sources in This Report
Table 42 : Agilent Technologies Inc.: Company Snapshot
Table 43 : Agilent Technologies Inc.: Financial Performance, FY 2022 and 2023
Table 44 : Agilent Technologies Inc.: Product Portfolio
Table 45 : Agilent Technologies Inc.: News/Key Developments, 2023
Table 46 : Altona Diagnostic GmbH.: Company Snapshot
Table 47 : Altona Diagnostic GmbH: Product Portfolio
Table 48 : Altona Diagnostic GmbH: News/Key Developments, 2021-2023
Table 49 : Analytik Jena GmbH+Co KG: Company Snapshot
Table 50 : Analytik Jena GmbH+Co KG: Product Portfolio
Table 51 : Analytik Jena GmbH+Co KG: News/Key Developments, 2023
Table 52 : BD: Company Snapshot
Table 53 : BD: Financial Performance, FY 2022 and 2023
Table 54 : BD: Product Portfolio
Table 55 : BD: News/Key Developments, 2021-2024
Table 56 : Bio-Rad Laboratories Inc.: Company Snapshot
Table 57 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2022 and 2023
Table 58 : Bio-Rad Laboratories Inc.: Product Portfolio
Table 59 : Bio-Rad Laboratories Inc.: News/Key Developments, 2022 and 2023
Table 60 : Danaher Corp.: Company Snapshot
Table 61 : Danaher Corp.: Financial Performance, FY 2022 and 2023
Table 62 : Danaher Corp.: Product Portfolio
Table 63 : Danaher Corp.: News/Key Developments, 2021-2023
Table 64 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 65 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 66 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 67 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2021-2023
Table 68 : Merck KGaA: Company Snapshot
Table 69 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 70 : Merck KGaA.: Product Portfolio
Table 71 : Merck KGaA: News/Key Developments, 2021-2024
Table 72 : Promega Corp.: Company Snapshot
Table 73 : Promega Corp.: Product Portfolio
Table 74 : Promega Corp.: News/Key Developments, 2023 and 2024
Table 75 : Qiagen: Company Snapshot
Table 76 : Qiagen: Financial Performance, FY 2022 and 2023
Table 77 : Qiagen: Product Portfolio
Table 78 : Qiagen: News/Key Developments, 2023
Table 79 : Revvity Inc.: Company Snapshot
Table 80 : Revvity Inc.: Financial Performance, FY 2022 and 2023
Table 81 : Revvity Inc.: Product Portfolio
Table 82 : Revvity Inc.: News/Key Developments, 2023 and 2024
Table 83 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 84 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 85 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 86 : Thermo Fisher Scientific Inc.: News/Key Developments, 2021-2024
List of Figures
Summary Figure : European Market for Life Science Tools and COVID-19 Diagnostics, by Product Type, 2021-2029
Figure 1 : Market Dynamics of European Life Science Tools and Reagents Market
Figure 2 : New Diagnostic Techniques
Figure 3 : Comparison of New Active Substances Approvals
Figure 4 : Comparison of European Patent Applications and Granted Patents, by Technical Field, 2011-2022
Figure 5 : European Market Shares of COVID-19 Diagnostics Tests, by Type, 2023
Figure 6 : European Market Shares of Life Science Tools and Reagents, by Type, 2023
Figure 7 : Types of ELISA
Figure 8 : Firms and R&D Investment in Health Industries, 2012 and 2022
Figure 9 : Pharmaceutical Pipeline Activity and Key Therapeutic Areas in Europe, 2022
Figure 10 : The U.K. Market for Life Science Tools and Reagents, 2024-2029
Figure 11 : German Market for Life Science Tools and Reagents, 2021-2029
Figure 12 : French Market for Life Science Tools and Reagents, 2021-2029
Figure 13 : Swiss Market for Life Science Tools and Reagents, 2024-2029
Figure 14 : Spanish Market for Life Science Tools and Reagents, 2024-2029
Figure 15 : Italian Market for Life Science Tools and Reagents, 2021-2029
Figure 16 : Rest of the European Market for Life Science Tools and Reagents, 2021-2029
Figure 17 : EPFIA's Environmental Sustainability Measures
Figure 18 : Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2023
Figure 19 : Agilent Technologies Inc.: Revenue Share, by Country/Region, FY 2023
Figure 20 : BD: Revenue Share, by Business Unit, FY 2023
Figure 21 : BD: Revenue Share, by Country/Region, FY 2023
Figure 22 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2023
Figure 23 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2023
Figure 24 : Danaher Corp.: Revenue Share, by Business Unit, FY 2023
Figure 25 : Danaher Corp.: Revenue Share, by Country/Region, FY 2023
Figure 26 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 27 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 28 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 29 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
Figure 30 : Qiagen: Revenue Share, by Business Unit, FY 2023
Figure 31 : Qiagen: Revenue Share, by Country/Region, FY 2023
Figure 32 : Revvity Inc.: Revenue Share, by Business Unit, FY 2023
Figure 33 : Revvity Inc.: Revenue Share, by Country/Region, FY 2023
Figure 34 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
Figure 35 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security